Abstract
Site directed drug delivery with high efficacy is the biggest challenge in the area of current pharmaceuticals. Biodegradable polymer-based controlled release nanoparticle platforms could be beneficial for targeted delivery of therapeutics and contrast agents for a myriad of important human diseases. Biodegradable nanoparticles, which can be engineered to load multiple drugs with varied physicochemical properties, contrast agents, and cellular or intracellular component targeting moieties, have emerged as potential alternatives for tracking and treating human diseases. In this review, we will highlight the current advances in the design and execution of such platforms for their potential application in the diagnosis and treatment of variety of diseases ranging from cancer to Alzheimer’s and we will provide a critical analysis of the associated challenges for their possible clinical translation.
Keywords: Active targeting, biomaterials, blood-brain barrier, cancer, cardiovascular diseases, liposome, neurodegenerative diseases, nanomedicine, nanotechnology, polymer, passive targeting.
Current Medicinal Chemistry
Title:Nanocarriers for Tracking and Treating Diseases
Volume: 20 Issue: 28
Author(s): Sean Marrache, Rakesh Kumar Pathak, Kasey L. Darley, Joshua H. Choi, Dhillon Zaver, Nagesh Kolishetti and Shanta Dhar
Affiliation:
- NanoTherapeutics Research Laboratory, Department of Chemistry, Room No. 679, University of Georgia, Athens, GA 30602, USA.,Georgia
Keywords: Active targeting, biomaterials, blood-brain barrier, cancer, cardiovascular diseases, liposome, neurodegenerative diseases, nanomedicine, nanotechnology, polymer, passive targeting.
Abstract: Site directed drug delivery with high efficacy is the biggest challenge in the area of current pharmaceuticals. Biodegradable polymer-based controlled release nanoparticle platforms could be beneficial for targeted delivery of therapeutics and contrast agents for a myriad of important human diseases. Biodegradable nanoparticles, which can be engineered to load multiple drugs with varied physicochemical properties, contrast agents, and cellular or intracellular component targeting moieties, have emerged as potential alternatives for tracking and treating human diseases. In this review, we will highlight the current advances in the design and execution of such platforms for their potential application in the diagnosis and treatment of variety of diseases ranging from cancer to Alzheimer’s and we will provide a critical analysis of the associated challenges for their possible clinical translation.
Export Options
About this article
Cite this article as:
Marrache Sean, Pathak Kumar Rakesh, Darley L. Kasey, Choi H. Joshua, Zaver Dhillon, Kolishetti Nagesh and Dhar Shanta, Nanocarriers for Tracking and Treating Diseases, Current Medicinal Chemistry 2013; 20(28) . https://dx.doi.org/10.2174/0929867311320280007
DOI https://dx.doi.org/10.2174/0929867311320280007 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Indications of Anti-Inflammatory Drugs in Cardiac Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Healthspan and Longevity in Mammals: A Family Game for Cellular Organelles?
Current Pharmaceutical Design Let Them Eat Cake
Current Nutrition & Food Science The Molecular Concept of Atheromatous Plaques
Current Drug Targets Effects of CYP2C19 Polymorphism on Endothelial Function, Arterial Stiffness and Inflammation in Coronary Artery Disease Patients Under Clopidogrel Treatment
Current Pharmaceutical Design Cellular Localisation of Chromogranins and Processed Products in the Diffuse Neuroendocrine System and Related Tumours
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents COVID-19: An Update on Pathogenesis and Treatment
Current Pharmaceutical Design Oleic Acid in Olive Oil: From a Metabolic Framework Toward a Clinical Perspective
Current Pharmaceutical Design Auraptene: A Natural Biologically Active Compound with Multiple Targets
Current Drug Targets Editorial (Thematic Issues: Autoimmunity and Autoinflammation: Cardiovascular Drug Targets and Design)
Current Pharmaceutical Design Post-stroke Depression Therapy: Where are we now?
Current Neurovascular Research Subject Index to Volume 3
Current Gene Therapy Pharmacological Targeting of IDO-Mediated Tolerance for Treating Autoimmune Disease
Current Drug Metabolism Diagnosis of Cardiovascular Diseases Using Retinal Images Through Vessel Segmentation Graph
Current Medical Imaging Editorial [Hot Topic : Current Practice and trends in echocardiography in Critical Care, Anesthesiology and Emergency Medicine (Guest Editor: Paulo Marcelino)]
Current Cardiology Reviews Cell Sources in Cardiac Tissue Engineering: Current Choices
Current Stem Cell Research & Therapy Endothelial Dysfunction Induced by Cadmium and Mercury and its Relationship to Hypertension
Current Hypertension Reviews Oxidative Stress and its Clinical Consequences: Relationship between Diabetes and Cancer
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Inhibition of Interleukin-1 in the Treatment of Selected Cardiovascular Complications
Current Reviews in Clinical and Experimental Pharmacology Hypoxia in Pre-Eclampsia: Cause or Effect?
Current Women`s Health Reviews